The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
The White House has pulled Heidi Overton’s nomination to be the Food and Drug Administration’s next commissioner after her views on vaccine policy, abortion drug access and flavored vapes caused her to lose critical support in the Senate.
The Senate Health, Education, Labor and Pensions Committee had scheduled a Wednesday vote to consider Overton’s confirmation along with multiple other nominations. The meeting was urgent, too, as the White House had hoped to have Overton in place while Republicans still retain control of Congress.
Yet a vote never occurred. On Tuesday, a published report from Axios indicated that the White House abandoned the effort after it appeared Overton wasn’t likely to succeed. At Wednesday’s hearing, Committee Chairman and Louisiana Republican Senator Bill Cassidy confirmed that outcome and expressed surprise, stating he’d been involved in “productive conversations” that had “convinced me that she would follow the science and push back against decisions that put Americans' lives at risk.”
“I think she would have had the votes to pass out of a committee and to pass the full Senate,” Cassidy said at the hearing. “Unfortunately, with the limited time left, confirming a permanent FDA commissioner appears to fall to Senate Democrats.”
The decision is likely to set back for months the Trump administration’s efforts to nominate a permanent FDA commissioner. That position has been occupied on an acting basis since May by Kyle Diamantas, the agency’s deputy commissioner for food.
Source link







